Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
Provided By GlobeNewswire
Last update: Jan 13, 2025
Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028
Study 1 of Essential3 program for ulixacaltamide in essential tremor (ET) on track for Q1 2025 interim analysis; NDA filing for ulixacaltamide expected in 2025
Read more at globenewswire.com
